問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Family Medicine

Division of General Internal Medicine

Division of Nephrology

更新時間：2023-09-19

陳怡婷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

17Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳怡婷

List

28Cases

2022-08-01 - 2023-08-14

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-01-01 - 2023-06-30

Phase III

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD

  • Condition/Disease

    Iron Deficiency Anemia With Non-Dialysis Dependent CKD

  • Test Drug

    PBF-1681

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2018-10-01 - 2022-02-28

Phase II

Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • Condition/Disease

    Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • Test Drug

    venglustat

Participate Sites
2Sites

Recruiting2Sites

2019-06-15 - 2023-09-14

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    Cemdisiran (ALN-CC5)

Participate Sites
6Sites

Recruiting6Sites

2020-11-30 - 2022-03-28

Phase II

A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)

  • Condition/Disease

    Membranous Nephropathy

  • Test Drug

    MOR202

Participate Sites
5Sites

Recruiting5Sites

2019-08-09 - 2022-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis

  • Condition/Disease

    Secondary Hyperparathyroidism

  • Test Drug

    KHK7580

Participate Sites
10Sites

Terminated10Sites

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2018-03-23 - 2020-04-14

Phase III

A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

  • Condition/Disease

    Secondary Hyperparathyroidism/Hemodialysis

  • Test Drug

    Parsabiv

Participate Sites
13Sites

Terminated13Sites

2021-05-31 - 2023-03-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB